Skip to Content

很抱歉,目前系统维护中。在此期间,网站下单功能无法使用。给您带来不便,深表歉意。如需其他帮助,请联系客户联络中心:400 620 3333。

Merck
CN
  • Ocular Graft-versus-Host Disease in a Chemotherapy-Based Minor-Mismatch Mouse Model Features Corneal (Lymph-) Angiogenesis.

Ocular Graft-versus-Host Disease in a Chemotherapy-Based Minor-Mismatch Mouse Model Features Corneal (Lymph-) Angiogenesis.

International journal of molecular sciences (2021-07-03)
Uta Gehlsen, Daniela Stary, Martina Maass, Katarina Riesner, Gwen Musial, Michael E Stern, Olaf Penack, Philipp Steven
ABSTRACT

Ocular graft-versus-host disease (oGVHD) is a fast progressing, autoimmunological disease following hematopoietic stem cell transplantation, leading to severe inflammation of the eye and destruction of the lacrimal functional unit with consecutive sight-threatening consequences. The therapeutic "window of opportunity" is narrow, and current treatment options are limited and often insufficient. To achieve new insights into the pathogenesis and to develop new therapeutic approaches, clinically relevant models of oGVHD are desirable. In this study, the ocular phenotype was described in a murine, chemotherapy-based, minor-mismatch GVHD model mimicking early-onset chronic oGVHD, with corneal epitheliopathy, inflammation of the lacrimal glands, and blepharitis. Additionally, corneal lymphangiogenesis was observed as part of oGVHD pathogenesis for the first time, thus opening up the investigation of lymphangiogenesis as a potential therapeutic and diagnostic tool.

MATERIALS
Product Number
Brand
Product Description

Roche
Liberase TL Research Grade, lyophilized, suitable for tissue processing, optimum pH 7.4
Sign Into View Organizational & Contract Pricing
SKUPack SizeAvailabilityPriceQuantity
10 mg
Estimated to ship on April 07, 2025
Details...
CN¥728.92